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Abstract
Background: Dengue virus-host cell interaction initiates when the virus binds to the attachment receptors followed by
endocytic internalization of the virus particle. Successful entry into the cell is necessary for infection initiation. Currently,
there is no protective vaccine or antiviral treatment for dengue infection. Targeting the viral entry pathway has become an
attractive therapeutic strategy to block infection. This study aimed to investigate the effect of silencing the GRP78 and
clathrin-mediated endocytosis on dengue virus entry and multiplication into HepG2 cells.
Methodology/Principal Findings: HepG2 cells were transfected using specific siRNAs to silence the cellular surface receptor
(GRP78) and clathrin-mediated endocytosis pathway. Gene expression analysis showed a marked down-regulation of the
targeted genes (87.2%, 90.3%, and 87.8% for GRP78, CLTC, and DNM2 respectively) in transfected HepG2 cells when
measured by RT-qPCR. Intracellular and extracellular viral RNA loads were quantified by RT-qPCR to investigate the effect of
silencing the attachment receptor and clathrin-mediated endocytosis on dengue virus entry. Silenced cells showed a
significant reduction of intracellular (92.4%) and extracellular viral RNA load (71.4%) compared to non-silenced cells. Flow
cytometry analysis showed a marked reduction of infected cells (89.7%) in silenced HepG2 cells compared to non-silenced
cells. Furthermore, the ability to generate infectious virions using the plaque assay was reduced 1.07 log in silenced HepG2
cells.
Conclusions/Significance: Silencing the attachment receptor and clathrin-mediated endocytosis using siRNA could inhibit
dengue virus entry and multiplication into HepG2 cells. This leads to reduction of infected cells as well as the viral load,
which might function as a unique and promising therapeutic agent for attenuating dengue infection and prevent the
development of dengue fever to the severe life-threatening DHF or DSS. Furthermore, a decrease of viremia in humans can
result in the reduction of infected vectors and thus, halt of the transmission cycle.
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Introduction
Monocytes and macrophages have been considered as the
primary targets of dengue virus (DENV) infection and are
responsible for replication and dissemination of the virus after
the onset of infection [1,2]. Recent studies have also shown that
the liver is an additional major target of DENV as supported by
many evidences, including hepatomegaly, liver dysfunction
[3,4,5], pathological findings [4,6,7,8,9], presence of viral antigens
and DENV RNA in hepatocytes and Kupffer cells [10,11], and
virus recovery from liver biopsies [12]. Furthermore, different
studies suggested that the severity and mortality of dengue
infection were related to the involvement of hepatic abnormality
and liver dysfunction in dengue hemorrhagic fever (DHF) and
dengue shock syndrome (DSS) [3,4,6].
The infectious entry of DENV into the target cells is critical to
establish the infection and is mediated by the viral E glycoprotein
in both attachments and internalization into the host cells
[13,14,15,16,17]. It comprises virion attachment to the cellular
surface receptor, internalization into the cytoplasm by endocytosis,
and finally release of nucleocapsid into the cytoplasm [18].
Currently multiple cell surface molecules were involved in DENV
binding to the target cells. Previous studies have implicated glucose
regulating protein 78 (GRP78) as a receptor on HepG2 cells
(Hepatocytes) for DENV-2 entry [19,20,21]. GRP78, a stress-
induced endoplasmic reticulum (ER) chaperone, is expressed at
basal levels in normal adult organs such as the brain, lung, and
liver. It is also reported on other cells such as proliferating
endothelial and monocytic cells, but it is overexpressed on the
membrane of malignant cells [22,23,24,25,26]. The critical role of
GRP78 in the unfolded protein response as a part of the ER
protein folding machinery has been well characterized [27]. It is
involved in major biological functions of the regulation of protein
folding and assembly, protein quality control, calcium binding and
regulating ER stress signaling, intracellular protein trafficking [28],
potent anti-apoptotic protein [29,30], cell surface receptor-mediated
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endocytosis [31], and as a cell-surface protein that functions as a
receptor in a range of cells [32]. Clathrin-mediated endocytosis has
been identified as the main endocytic entry pathway for DENV
[33,34,35]. Clathrin-mediated endocytosis pathway plays an essen-
tial role in the formation of coated vesicles, nutrient acquisition,
clearance of apoptotic cells, antigen presentation, pathogen entry,
receptor regulation, hypertension, and synaptic transmission.
RNA interference (RNAi) is a potent sequence-selective post-
transcriptional gene control mechanism [36] and is mediated by
small interfering RNAs (siRNA) [37,38]. It has the advantage of
significantly enhanced potency, specificity, and versatility com-
pared to other traditional gene silencing methods [39,40]. Since
the first report on RNAi-mediated inhibition of respiratory
syncytial virus (RSV) [41], several proof-of-concept studies have
shown that pre-treatment or co-treatment with a virus-specific
siRNAs can be used to inhibit the expression and/or replication of
numerous viruses in vitro and in vivo [42] including HIV [43], HBV
[44,45], HCV [44,46], WNV [47], CMV [48], and influenza virus
[49]. Similarly, down regulation of cellular entry mechanisms
using RNAi has a potential inhibitory effect on the DENV entry
and multiplication into the target cells [50,51,52]. We observed
previously that silencing CD14 associated molecule and clathrin-
mediated endocytosis in human monocytes could inhibit entry and
multiplication of DENV [50]. Thus, this study was proposed to use
RNAi to attenuate dengue infection based on this observation as
well as on the evidences that have showed the critical role of
hepatocytes in dengue infection and progression to the severe life-
threatening form of the disease [10,53,54,55]. This was achieved
by specifically silencing the GRP78 as an attachment receptor in
HepG2 cells. In addition, two main components of the clathrin-
mediated endocytosis pathway have also been carefully chosen;
Clathrin heavy polypeptide (CLTC) which is required for clathrin-
coated pits formation, and Dynamin 2 (Human-DNM2) which is
essential for pinching off the endocytic vesicles from the plasma
membrane.
Materials and Methods
Cells and virus
HepG2 was purchased from the American Type Culture
Collection (cat #: HB-8065, ATCC, USA). Cells were maintained
in DMEM supplemented with 10% FBS, 3.8 g/L sodium
bicarbonate, 100 U/mL penicillin, and 100 mg/mL streptomycin
at 37uC in 5% CO2. The experiments were performed using
HepG2 cells with passage number between 10 and 35.
DENV-2 strain New Guinea C (NGC) was propagated in C6/
36 cells (cat #: CRL-1660, ATCC, USA) and stored at 280uC
until used as described previously [56]. Virus was titrated using the
plaque assay on porcine kidney cells (PS clone D) as described
previously [57]. PS clone D cells were sourced from Department of
Medical Microbiology, Faculty of Medicine, University Malaya.
siRNA design and synthesis
The nucleotide sequences of the GRP78 (NM_005347), CLTC
(NM_004859), and DNM2 (NM_001005360) transcripts were
retrieved from GenBank. siRNA sequences were designed by using
the web-based tool IDT SciTools RNAi Design available from
Integrated DNA Technologies (IDT), Inc. at www.idtdna.com.
Three siRNAs were designed for each gene (Table 1). The
specificity of the designed siRNA to the target gene is confirmed by
BLAST searching online at (http://www.ncbi.nlm.nih.gov/
BLAST) [58]. A pool consists of the three-siRNA oligonucleotides
for each gene was custom chemically synthesized by 1st BASE Pte
Ltd, Singapore. One pre-validated siRNA targeting GAPDH gene
as a positive siRNA control and one scramble siRNA as negative
siRNA control were included in this study. The synthesized
siRNAs were purified by HPLC, and a 29-O-methyl modification
at position 2 was introduced to deactivate the off-target activity of
the siRNA without compromising the silencing effectiveness [59].
siRNA transfection
HepG2 cells were transfected using DharmaFECT-4 siRNA
Transfection Reagent (Thermo Fisher Scientific, USA) by reverse
transfection method in 24-well plate. For each well, suspension of
16105 cells were mixed with a mixture of siRNA-transfection
reagent complex to deliver final concentrations of 50 nM of each
GRP78, CLTC and DNM2 siRNA. The positive control was
transfected with pre-validated siRNA targeting GAPDH gene.
The negative control received the DharmaFECT-4 Transfection
Reagent plus the scramble siRNA. For monitoring the gene
silencing effect, cells were harvested after 24 hours; while for
evaluating the viral entry after infection with DENV-2, cells were
harvested after 72 hours.
Cytotoxicity
Cytotoxicity was tested using CytoTox-ONETM Homogeneous
Membrane Integrity Assay (Promega, USA) that measure LDH
released from cells with compromised membrane in accordance to
the manufacturer’s protocol.
Gene knockdown verification
Gene expression analysis of the target genes was performed by
RT-qPCR usingCFX96TM Real-Time PCR Detection System
(Bio-Rad, USA). Primer sets for GRP78, CLTC, DNM2, RPL27,
and GAPDH were designed by using Primer Express software
V3.0. Primer set for RPS29 was obtained from published
sequences [60] (Table 2). A pair of primer was considered valid
when the efficacy of amplification is between 90–110% with a
minimum R2 of 0.980. Reference genes for this study were
identified by using geNorm v3.5 software [61]. The RT-qPCR
protocol and reaction conditions were carried out as described
previously [50]. RT-qPCR experiments were performed in three
technical replicates, and no template control and no-reverse
Table 1. Sequences of siRNA oligonucleotide template.
siRNA Nucleotide sequence (sense strand) Positiona
GRP 78 (1) 59r(GAAGGUUACCCAUGCAGUUGUUACT)39 750–774
GRP 78 (2) 59r(AGAUGAAGCUGUAGCGUAUGGUGCT)39 1431–1455
GRP 78 (3) 59r(CCACCAAGAUGCUGACAUUGAAGAC)39 2082–2106
CLTC (1) 59r(AGCCAGGACCCAGAUGUFC)39 2607–2625
CLTC (2) 59r(AUGUAUGAUGCUGCUAAGU)39 4071–4089
CLTC (3) 59r(CUCCACCAAUGACCUUAGA)39 7964–7982
DNM2 (1) 59r(GAAGGACAUCCGUGCAGCACUGGCA)39 925–949
DNM2 (2) 59r(GUACCAGUAAGCUCAGUUCCUACCC)39 1515–1539
DNM2 (3) 59r(CCCUUGACACCAUCCUGAAUGAGGG)39 3075–3099
GAPDH 59r(GAACAUCAUCCCUGCCUCUACUGGC)39 714–738
Scrambleb 59r(ATGGACAGAATAAATGGACTT)39
Three siRNAs for each target gene were designed. The experiment includes also
one Positive control siRNA for GAPDH gene and one scramble siRNA.
aThe position refers to the siRNA sequence position on the target gene.
bScrambled siRNA is a control used to markup any changes to the gene
expression profile that may result from the siRNA delivery method.
doi:10.1371/journal.pone.0034060.t001
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transcription control were also included. Baseline and quantifica-
tion cycle (Cq) values and gene expression analysis were
automatically analyzed using the Bio-Rad CFX Manager Software
1.6.
HepG2 cells infection
Infection of silenced and non-silenced HepG2 cells was
performed at a density of 16105 cells in a 24-well plate as
described previously [50]. After 72 hours, cellular supernatant
were collected and stored in aliquot at 280uC until use for
infectious virion titration by plaque assay and viral RNA copies
quantification by RT-qPCR while cells were harvested for
counting the infected cells by flow cytometry and viral RNA
quantification by RT-qPCR.
Viral RNA quantification
One-step RT-qPCR was carried out in CFX96TM Real-Time
PCR Detection System using the iScriptTM One-Step RT-PCR
Kit with SYBRH Green as described previously [50]. Three
technical replicates were carried out for each sample and no
template control was included as a negative control.
Flow cytometry analysis
Silenced and non-silenced DENV-2 infected and non-infected
HepG2 cells (control) were harvested for flow cytometric
quantification of DENV infected cells as described previously
[50,62]. Flow cytometry analysis was performed using indirect
staining in which monoclonal antibody (anti-DENV-2 for
detection of positive samples and anti-DENV-3 as a negative
control) was used as a primary antibody. The cells were then
incubated with a FITC-labeled goat anti-mouse IgG as a
secondary antibody. During flow cytometry, 100,000 events were
acquired on a FACScaliber using Cell Quest software (Becton
Dickinson Immunocytometry System, CA). The percentage of
positive cells and the average fluorescence intensities were
determined from FITC fluorescence histogram using a region
that was defined based on analysis of the infected control.
Statistical analysis
Cytotoxicity assay, gene expression analysis, HepG2 transfec-
tion and infection, flow cytometry detection of infected cells, and
intracellular and extracellular quantification of viral RAN by RT-
qPCR were done at least in three biological experiments. All
statistical analyses were performed using GraphPad Prism version
5.01 (GraphPad Software, USA). P values,0.05 were considered
significant. Results are expressed as mean 6 SD from a
representative experiment performed in triplicate.
Results
Cytotoxicity and optimization of siRNA transfection
The transfection experiment was optimized to produce
maximum silencing with minimal or no cytotoxicity. Cytotoxicity
was determined by measuring the levels of released LDH from
cells with compromised membrane. Transfection experiment was
optimized by treating the HepG2 cells with increasing concentra-
tions of siRNA and transfection reagent. Results show that efficient
silencing with minimal cytotoxicity was achieved using 1 ml of
transfection reagent. No evidence of toxicity was shown regardless
of the concentration of siRNA compared with scramble siRNA
transfected HepG2 cells (One-way ANOVA with Dunnett’s post-
test, P.0.05). The optimal siRNA concentration is 50 nM for
GRP78, CLTC, and DNM2 (Figure 1).
After optimization, transfection experiments were carried out at a
cell density of 1.06105 cells/well in a 24-well plate using 1.0 mL
DharmaFECT-4 siRNA transfection reagent and siRNA concen-
tration of 50 nM for GRP78, CLTC, and DNM2. This transfection
condition showed a minimal toxicity effect on the transfected cells.
The percentages of the viable cells were 91.6%62.0, 90.7%61.9,
90.5%60.4, and 89.9%61.8 for GRP78, CLTC, DNM2, and
combined transfection respectively compared with non-transfected
HepG2 cells (One-way ANOVA with Dunnett’s post-test, P.0.05).
This observation was further confirmed by counting the number of
viable cells using Trypan Blue exclusion assay that showed more
than 90% of the cells were viable as shown in Figure 1.
Gene knockdown verification
The effect of siRNA transfection on related gene expression was
investigated by RT-qPCR using mRNA extracted from the
transfected HepG2 cells. Gene expression results were shown as
normalized-fold expression compared to non-transfected control.
Firstly, the silencing efficiency of the pooled siRNAs, which
comprised of the three different siRNAs targeting the same gene,
was screened. As shown in Figure 2, the knockdown levels were
87.1%60.9, 90.5%60.5, and 87.4%61.0 for pooled siRNA of
GRP78, CLTC, and DNM2 respectively (One-way ANOVA with
Dunnett’s post-test, P,0.0001). HepG2 cells were then co-
transfected with a combination of the three different siRNA pools
to target the three genes simultaneously. Result showed no
significant differences in the knockdown level for all the genes
(87.2%61.0, 90.3%60.9, and 87.8%61.6 for GRP78, CLTC,
and DNM2 respectively) when compared to separated transfection
(Two-way ANOVA with Bonferroni post-test, P.0.05). Further-
more, no inhibitory effect on any gene expression was observed in
the scramble siRNA transfected HepG2 cells as shown in Figure 2
(One-way ANOVA with Dunnett’s post-test, P.0.05).
Table 2. Primer sequences.
Accession number Gene symbol Forward sequence (59R39) Reverse sequence (59R39) (bp)
(NM_005347) GRP78 ACTATGAAGCCCGTCCAGAA GACAGCAGCACCATACGCTA 189
(NM_004859) CLTC CCACAATACTCCACCAATGACCTTA CCCATTTTAAGTGGCTCCACCTCTC 97
(NM_001005360) DNM2 GGCATTCGAGGCCATTGT CATTTCAGACAGGGCTCTTTCA 60
(NM_002046) GAPDH CATCACCATCTTCCAGGAGCG TGATGGCATGGACTGTGGTC 326
(NM_000988) RPL27 CATGGGCAAGAAGAAGATCG ACGACAGTTTTGTCCAAGGG 120
(NM_001030001) RPS29 GCACTGCTGAGAGCAAGATG ATAGGCAGTGCCAAGGAAGA 213
(NC001477) DENV_NS5 GGAAGGAGAAGGACTGCACA ATTCTTGTGTCCCATCCTGCT 104
Primer sequences of the target genes, positive control gene, optimal reference genes and DENV NS5.
doi:10.1371/journal.pone.0034060.t002
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Quantification of infected HepG2 cells
Dengue infected HepG2 cells were quantified to determine
whether silencing of GRP78 and/or clathrin endocytosis pathway
could inhibit DENV entry into HepG2 cells and, therefore, reduce
its multiplication. Both silenced and non-silenced HepG2 cells
were infected with DENV-2 at a MOI of 2. Result showed a
marked reduction in the percentage of infected cell in GRP78,
CLTC, and DNM2 silenced HepG2 by using flow cytometry. The
Figure 1. Cytotoxicity and optimization of siRNA transfection. HepG2 cells transfection experiment was optimized by treating the HepG2
cells with increasing amount of transfection reagent and concentrations of siRNA. (a) Result shows that the efficient silencing with minimal
cytotoxicity was achieved using 1.0 ml of transfection reagent. (b) HepG2 cells transfected with increased concentration of GRP78 siRNAs and the
result shows no evidence of toxicity regardless of the siRNA concentration as compared with scramble siRNA transfected HepG2 cells (One-way
ANOVA with Dunnett’s post-test, P.0.05). The optimal siRNA concentration is 50 nM. Similar results were observed in (c) CLTC siRNAs and (d) DNM2
siRNAs. (e) HepG2 cells were transfected and exposed to optimal siRNAs concentration (50 nM) that target GRP78, CLTC, and DNM2 in separated and
combined transfection. Cytotoxicity was tested by measuring LDH level and results were confirmed by counting of viable cells using Trypan Blue
exclusion assay. No evidence of cytotoxicity was observed for all pools of siRNA as well as in combined transfection (91.6%62.0, 90.7%61.9,
90.5%60.4, and 89.9%61.8 for GRP78, CLTC, DNM2, and combined transfection respectively). Trypan Blue exclusion assay showed also more than
90% viable cells. No significant difference was observed between separated and combined transfection by One-way ANOVA analysis (P.0.05). Results
are expressed as mean 6 SD from a representative experiment performed in triplicate.
doi:10.1371/journal.pone.0034060.g001
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percentage of infected cells was reduced from 45.7%67.0 in
scramble siRNA transfected HepG2 cells to 8.5%60.3 (81.3%),
8.5%61.2 (81.4%), and 15.2%63.6 (66.6%) in GRP78, CLTC,
and DNM2 silenced HepG2 cells respectively. Interestingly,
combined silencing (GRP78, CLTC, and DNM2) of HepG2 cells
showed a higher inhibitory effect on DENV entry and replication
(4.7%61.8) which represented 89.7% reduction in infected cells
compared to scramble siRNA transfected HepG2 cells as shown in
Figure 3 (One-way ANOVA with Dunnett’s post-test, P,0.0001).
Furthermore, statistical analysis of the results shows no significance
difference between the scramble siRNA transfected and non-
transfected infected HepG2 cells (One-way ANOVA with
Dunnett’s post-test, P.0.05).
Quantification of intracellular viral RNA load
The reduction of the percentage of infected cell in silenced
HepG2 cells was further confirmed by quantification of intracel-
lular viral RNA load using RT-qPCR analysis. The viral RNA
load in silenced HepG2 cells was compared to the scramble siRNA
transfected HepG2 cells and was normalized to the reference gene
(RPL27). Data is expressed as relative-fold expression to scramble
siRNA transfected HepG2 cells, which was defined as 1.0 fold
(viral RNA copy number is 1.216104/mL). Result showed a
significant reduction of DENV RNA level in silenced HepG2 cells:
0.72 fold 60.11, 0.67 fold 60.04, 0.61 fold 60.04, and 0.92 fold
60.004 in GRP78, CLTC, DNM2, and combined silenced
HepG2 cells respectively as shown in Figure 4 (One-way ANOVA
with Dunnett’s post-test, P,0.0001). Again, there is no significant
difference between the scramble siRNA transfected and non-
transfected infected HepG2 cells (One-way ANOVA with
Dunnett’s post-test, P.0.05).
Quantification of viral RNA load and plaque forming units
in culture supernatant
DENV excreted from the silenced HepG2 cells into the culture
supernatant was quantified by RT-qPCR and compared to
scramble siRNA transfected HepG2 cells. Result showed a similar
observation when compared to the intracellular quantification of
viral RNA. Figure 5 described the DENV RNA load in the culture
supernatant of silenced HepG2 cells as compared to scramble
siRNA transfected HepG2 cells, which was defined as 100% (viral
RNA copy number is 6.506104/mL). The reduction in viral RNA
was 65.1%61.7, 65.4%69.8, 60.9%610.6, and 71.4%65.7 for
GRP78, CLTC, DNM2, and combined silenced HepG2 cells
respectively. This result is statistically significant (One-way
ANOVA with Dunnett’s post-test, P,0.0001). To confirm the
previous results, DENV virus titer was determined by plaque assay
from the harvested culture medium 72 hours post infecting the
transfected HepG2 cells. Plaques were counted at day 7 of
incubation. Plaques are expressed as plaque forming unit per mL
(pfu/mL). Result showed a dramatically reduction in the ability to
generate infectious virions in silenced HepG2 cells. The reduction
in the plaque forming units was 0.56, 0.41, and 0.34 log in
separated silencing of GRP78, CLTC, DNM2 respectively.
Furthermore, the titer of the plaque forming units was reduced
up to 1.07 log in the combined silencing of GRP78, CLTC, and
DNM2 in HepG2 cells compared to scramble siRNA transfected
HepG2 cells as shown in Figure 6 (One-way ANOVA with
Dunnett’s post-test, P,0.0005).
Discussion
The present study investigates the effects of siRNA on
suppression the dengue infection in HepG2 cells by silencing the
GRP78, CLTC, and DNM2 genes separately or in combination.
The silenced HepG2 cells with specific siRNA duplexes (GRP78,
CLTC, and DNM2) revealed a reduction of the percentage of
infected cells as shown by flow cytometry analysis, reduction of the
intracellular and extracellular viral RNA load when monitored by
RT-qPCR, and reduction of generation of infectious virions as
observed by plaque assay. The findings have shown that the
suppression was specific and efficient. This results are consistent
Figure 2. Efficiency of silencing target genes. Each of target genes was targeted with a specific pool of siRNA. An efficient gene silencing was
achieved in both separated and combined transfection when compared with non-transfected control and normalized to reference genes (One-way
ANOVA with Dunnett’s post-test, P,0.0001, Results are expressed as mean6 SD from a representative experiment performed in triplicate). There are
no significant differences between separated transfection (87.1%60.9, 90.5%60.5, and 87.4%61.0) and combined transfection (87.2%61.0,
90.3%60.9, and 87.8%61.6) on gene expression of GRP78, CLTC, and DNM2 respectively (Two-way ANOVA with Bonferroni post-test, P.0.05, Results
are expressed as mean6 SD from a representative experiment performed in triplicate). Scrambled siRNA control had no inhibitory effect on any gene
expression, and a similar expression to the non-transfected control was observed (One-way ANOVA with Dunnett’s post-test, P.0.05).
doi:10.1371/journal.pone.0034060.g002
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with our previous findings of inhibition of dengue infection in
monocytes by silencing the CD-14 associated molecule and
clathrin-mediated endocytosis [50]. Our previous study has
showed a significant reduction of infected cells (85.2%), intracel-
lular viral RNA load (73.0%), and extracellular viral RNA load
(63.0%) in silenced monocytes as compared to non-silenced
Figure 3. Quantification of infected cells by flow cytometry. Silenced and non-silenced HepG2 cells were infected by DENV-2 at MOI of 2.
Result showed a marked reduction in percentage of infected cells by flow cytometry. This figure shows the percentage of DENV infected cells at
different conditions. (a) Transfected non-infected HepG2 cells (0.0%) represent the negative control. (b) Transfected mock-infected HepG2 cells as a
staining control (0.0%). (c) Scramble siRNA transfected infected HepG2 cells (45.7%) as a positive control. (d) GRP78 silenced infected HepG2 cells
(8.5%). (e) CLTC silenced infected HepG2 cells (8.5%). (f) DNM2 silenced infected HepG2 cells (15.2%). (g) GRP78, CLTC, and DNM2 combined silenced
infected HepG2 cells (4.7%). (h) Summarized the results of the flow cytometry experiments. Data is expressed as a percentage of infected cells
compared with scramble siRNA transfected infected HepG2 cells which was defined as 100%. The percentages of the infected cells are 18.7%60.7,
18.6%62.6, 33.4%67.9, and 10.3%63.9 for GRP78, CLTC, DNM2, and combined silenced HepG2 cells respectively (One-way ANOVA with Dunnett’s
post-test, P,0.0001, Results are expressed as mean6 SD from a representative experiment performed in triplicate). Also, statistical analysis shows no
significant difference between scramble siRNA transfected and non-transfected infected HepG2 cells (One-way ANOVA with Dunnett’s post-test,
P.0.05).
doi:10.1371/journal.pone.0034060.g003
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monocytes. As seen in the current study, silenced HepG2 cells
showed a more efficient reduction of infected cells (89.7%),
intracellular viral RNA load (92.4%), and extracellular viral RNA
load (70.7%) compared to monocytes. This variation could be
attributed to the more effectiveness of the gene silencing in HepG2
cells than in monocytes as well as the monocytes are primary cells,
whereas the HepG2 cells are a cell line.
In dengue infection, evidences have shown that the liver is a
major target organ for DENV infection in humans as many
pathological findings and liver dysfunction have been detected in
the livers of DHF/DSS patients and is a characteristic of severe
dengue infection [10,53,54,55]. It has been demonstrated that
there is a direct correlation between the development of the severe
and life-threatening form of the disease and high viral load [63].
Hepatocytes were considered as a target in this study to reduce the
dengue viral load during the course of infection based on evidences
of its crucial role in dengue infection, and the previous findings of
the inhibition of dengue infection in monocytes. Prevention the
multiplication of DENV in the main target cells could result in
reduction of the total viral load during the course of infection. This
would potentially prevent the progression of dengue fever to the
severe life-threatening form of dengue infection. Furthermore, a
Figure 4. Quantification of intracellular dengue virus RNA load. Viral RNA levels were quantified by RT-qPCR and normalized to reference
gene (RPL27). Data is expressed as relative-fold expression to scramble siRNA transfected HepG2 cells control, which defined as 1.0 fold. Intracellular
viral RNA load reduced (0.72 fold 60.11), (0.67 fold 60.04), (0.61 fold 60.04), and (0.92 fold 60.004) in GRP78, CLTC, DNM2, and combined silenced
HepG2 cells respectively (One-way ANOVA with Dunnett’s post-test, P,0.0001, Results are expressed as mean 6 SD from a representative
experiment performed in triplicate). No significant difference between scramble siRNA transfected and non-transfected infected HepG2 cells (One-
way ANOVA with Dunnett’s post-test, P.0.05). (TNI, Transfected Non-Infected; NTI, Non-Transfected Infected; NTNI, Non-Transfected Non-Infected).
doi:10.1371/journal.pone.0034060.g004
Figure 5. Quantification of extracellular dengue virus RNA load. RT-qPCR was used to quantify the DENV RNA in the culture supernatant of
silenced and non-silenced HepG2 cells. Marked reduction in viral RNA was achieved (65.1%61.7), (65.4%69.8), (60.9%610.6), and (71.4%65.7) for
GRP78, CLTC, DNM2, and combined silenced HepG2 cells respectively. This result is statistically significant (One-way ANOVA with Dunnett’s post-test,
P,0.0001, Results are expressed as mean 6 SD from a representative experiment performed in triplicate). There is no significant difference between
scramble siRNA transfected and non-transfected infected HepG2 cells (One-way ANOVA with Dunnett’s post-test, P.0.05). (TNI, Transfected Non-
Infected; NTI, Non-Transfected Infected; NTNI, Non-Transfected Non-Infected).
doi:10.1371/journal.pone.0034060.g005
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decreased of viremia in humans can result in the drop in number
of infected vectors and, therefore, break of the transmission chain.
There are various strategies to develop antiviral agents against
DENV. Recently, the virus entry step has become an attractive
therapeutic strategy [64]. DENV-host cell interaction is initiated
with the virus binding on attachment receptors on the cell surface
followed by stimulation of signals that result in the endocytic
internalization of the virus particles. This is critical for successful
entry into the host cell and the establishment of infection. This
study was designed to target the GRP78 that has been identified as
receptor on HepG2 cells for DENV-2 entry [19,20,21], and
clathrin-mediated endocytosis that known as the main pathway for
virus internalization [65]. This is a possible way to provide a new
therapeutic strategy by targeting the host factors known to be
involved in viral infection. Thus, it is expected to control viral
infection by making the cellular receptors for viruses on human
cells less accessible. Recent studies showed that design and
synthesis of agents that prevent DENV binding and entry to the
cellular receptor sites could prove to be novel antiviral agents of
preventing the disease. RNAi pathway shows a role in modulating
DENV replication in previous studies [50,51,52].
In the present study, the designed siRNA showed an efficient
knockdown of the target genes when evaluated at the mRNA level
24 hours after transfection. To evaluate the viral entry into
HepG2 cells, the silenced cells were infected with a live DNEV
72 hours post transfection to confirm that the target proteins level
was reduced as the half-life time of these target proteins is less than
72 hours as shown by previous studies. These proteins possess a
half-life of 24–48 hours for GRP78 [66,67,68,69,70,71], 18–
36 hours for CLTC [72,73,74], and 24–34 hours for DNM2 [75].
Silencing the GRP78 and clathrin-mediated endocytosis
resulted in significant inhibition of dengue infection up to 81.3%
and 81.4% for GRP78 and the clathrin-mediated endocytosis
respectively. In addition, a more potent inhibition (up to 89.7%) is
observed when a combined silencing of both GRP78 and clathrin-
mediated endocytosis was done simultaneously. This reduction in
viral yield was not due to cell death as could be identified by
cytotoxicity and viability tests (.90% live cells) in both silenced
and non-silenced HepG2 cells. GRP78 could be up regulated in
dengue infected cells as a direct response to productive infection in
dengue infected cells and as a secondary consequence, in both
dengue infected and bystander cells, of the release of cytokines and
factors from dengue infected cells that can induce GRP78
expression. Previous studies have suggested two roles for GRP78
in dengue infection. First, GRP78 serves as part of a receptor
complex for DENV entry into hepatocytes [19,20,21]. Additionally,
heat shock treatment of cells in the tissue culture system prior to
DENV challenge, which would be expected to up regulate both
GRP78 and HSP70, thus enhancing DENV entry and replication
[76]. Second, GRP78 is known to function as a major ER
chaperone and master regulator of unfolded protein responses [77].
Dengue infection and viral protein production results in ER stress
[78]. An overwhelming load of misfolded proteins up regulate the
GRP78 [79]. Increasing the requirement of GRP78 triggers a
signaling of unfolded protein response (UPR) pathway [80]. Thus,
the UPR pathway restores the normal function of the cell by
enhancing transcription of ER chaperones, decreasing protein
translation to mitigate the ER overload, increasing protein
degradation, or activates the apoptotic cell death [78,81,82]. In
this study, silencing GRP78 showed inhibition of dengue infection
in HepG2 cells. Based on above explanation, we propose that
GRP78 inhibits dengue infection either by interaction with cell-
surface attachment and internalization and then multiplication. The
other possible way is that GRP78 may function in its traditional role
in binding and chaperoning many unfolded proteins, include
DENV proteins [83]. Our result is consistent with a previous
observation showing that cleaving the GRP78 by SubAB toxin can
dramatically reduce the releasing of infectious DENV and
intracellular virion particles [84]. Another study also shows the
siRNA knockdown of GRP78 in HepG2 cells decreased infectious-
virus production [85]. Furthermore, elimination of GRP78 leads to
reduction of cytosolic ubiquitination and inhibits ubiquitination-
proteosome pathway which is known to regulate the endocytosis of
cell-surface receptors [86,87]. Therefore, inhibiting the cellular
endocytosis pathway possibly leads to inhibit the internalization of
DENV [14,51] and other flaviviruses [88].
Figure 6. Quantification of plaque forming infectious virions in culture supernatant. The ability to produce infectious virions was
investigated by plaque assay. Figure shows marked reduction of the plaque forming units (0.56 log), (0.41 log), (0.34 log), and (1.07 log) for GRP78,
CLTC, DNM2, and combined silenced HepG2 cells respectively compared to scramble siRNA transfected cells. All plaques were counted at day 7 of
incubation. Plaques are expressed as plaque forming unit per mL (pfu/mL). This result is statistically significant (One-way ANOVA with Dunnett’s post-
test, P,0.0001, Results are expressed as mean 6 SD from a representative experiment performed in triplicate) and there is no significant difference
between scramble siRNA transfected and non-transfected infected HepG2 cells (One-way ANOVA with Dunnett’s post-test, P.0.05). (TNI, Transfected
Non-Infected; NTI, Non-Transfected Infected; NTNI, Non-Transfected Non-Infected).
doi:10.1371/journal.pone.0034060.g006
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Incomplete inhibition of dengue infection can be interpreted as
the result of using an alternative secondary receptor or endocytosis
by the DENV to establish the infection or incomplete inhibition by
the RNAi machinery. For RNAi based therapy designing, it is
necessary to consider that this technology knockdown gene
expression, but in general does not eliminate it. Therefore, in
some conditions, incomplete down regulation of a pathogenic gene
seems to be adequate to produce a clinically appropriate
improvement [40].
The approach of gene silencing is a widely accepted technique
and, recently, RNAi technique had shown a potential to achieve
the gene therapy goal [89]. The effectiveness of siRNA as a
therapy against dengue infection will depend on the efficiency of
siRNA delivery to the target mammalian cells [90]. However, for
application of RNAi as a dengue therapeutic, an effective and cell-
specific in vivo delivery system is required. Recently, several studies
have described a success in siRNAs delivery, in vivo, by coupling to
antibodies or peptides that recognize cell surface receptors [91].
This can provide a further supporting and future potential for the
practical utility of this approach. The aim of any therapeutic is to
maximize the ratio of desired effects to undesired effects. In some
cases, such as chemotherapy, interferon treatment, and highly
active anti-retroviral treatment, the ratio is not ideal and a
significant degree of toxicity is associated with treatment. While
RNAi has the capacity to provide better gene targeting specificity,
the exposure of cells to any exogenous molecule (siRNA or
transfecting reagent) has the potential to disturb normal cellular
functions and needs to be carefully controlled. In this study, the
transfection experiment was optimized to produce maximum
silencing effect at low-cell toxicity as revealed by measurement the
released LDH from cells with compromised membrane and
Trypan Blue exclusion assays in cell viability test.
One of the potential weaknesses of the RNAi based therapeutic
is the problem of resistance and RNAi escape mutations [40]. This
problem will probably require the use of RNAi in combination
therapy approaches, including multiple RNAi target sequences
and/or other synergistic antiviral drugs as well as by targeting the
host factors known to be involved in viral infection, such as entry
receptor or binding molecules on the susceptible cells. Here, we
used three different siRNA pools targeting GRP78, CLTC, and
DNM2. Each pool achieved its own silencing level and similar
knockdown efficiency of these genes in HepG2 cells was achieved
by co-transfection of the three pools simultaneously. The desire to
pool three siRNAs was raised primarily from the finding that the
silencing efficiency of a single siRNAs was lesser than combined
pool of triple siRNAs. These pools have shown a greater potency
in the reduction of the target gene expression and elimination of
off-targets effect.
Conclusions
We have successfully inhibited the DENV entry and multipli-
cation into HepG2 cells by silencing the GRP78 and clathrin
mediated endocytosis. Reduction of the viral load would
potentially prevent dengue fever and the severe life-threatening
form of dengue infection. Decreasing viremia in humans can result
in a decline in the infected vectors numbers, and thus interruption
of the transmission chain. This might not only save lives but also
curb potential epidemics. This tool might serve as a novel
promising therapeutic agent for the attenuation of dengue
infection and reduction the progression to severe form of the
disease DHF.
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